X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.290
+0.150 (3.62%)
Apr 17, 2026, 4:00 PM EDT - Market closed
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 45 employees as of December 31, 2025. The number of employees decreased by 98 or -68.53% compared to the previous year.
Employees
45
Change (1Y)
-98
Growth (1Y)
-68.53%
Revenue / Employee
$780,289
Profits / Employee
-$1,759,978
Market Cap
390.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 45 | -98 | -68.53% |
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| Cabaletta Bio | 156 |
| Nautilus Biotechnology | 130 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 96 |
| Avalo Therapeutics | 33 |
| Ovid Therapeutics | 23 |
| Monopar Therapeutics | 22 |
XFOR News
- 17 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 2 months ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 5 months ago - X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference - GlobeNewsWire
- 5 months ago - X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - GlobeNewsWire